利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.038 秒)

    Recombinantly produced antibody
    1.
    发明授权
    Recombinantly produced antibody 有权
    重组产生的抗体

    公开(公告)号：US09255147B2

    公开(公告)日：2016-02-09

    申请号：US13448755

    申请日：2012-04-17

    申请人： Larry R. Pease ,  Virginia Van Keulen ,  Bogoljub Ciric

    发明人： Larry R. Pease ,  Virginia Van Keulen ,  Bogoljub Ciric

    IPC分类号： C07K16/28 ,  A61K39/00

    CPC分类号： C07K16/2827 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/75

    摘要： An antibody capable of potentiating immune responses and modifying existing states of immune responsiveness is described, as is the sequence of the antibody. Also described are compositions containing the antibody, as well as methods for using the antibody and the compositions to enhance immune responses, to enhance DC function, to modify an existing state of immune responsiveness, to immunize individuals, or to treat or inhibit conditions such as allergic asthma.

    摘要翻译： 描述了能够增强免疫应答并改变现有的免疫应答状态的抗体，抗体的序列也是如此。 还描述了含有抗体的组合物，以及使用抗体和组合物来增强免疫应答，增强DC功能，改变现有的免疫应答状态，免疫个体或治疗或抑制诸如 过敏性哮喘

    HUMAN ANTIBODIES AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASE
    2.
    发明申请
    HUMAN ANTIBODIES AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASE 审中-公开
    用于治疗神经病的人体抗体及其诊断和治疗用途

    公开(公告)号：US20130280167A1

    公开(公告)日：2013-10-24

    申请号：US13880415

    申请日：2011-10-19

    申请人： Moses Rodriguez ,  Arthur E. Warrington ,  Larry R. Pease

    发明人： Moses Rodriguez ,  Arthur E. Warrington ,  Larry R. Pease

    IPC分类号： A61K39/395

    CPC分类号： A61K39/39541 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/74 ,  C07K2317/94

    摘要： Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful for neuroprotection and in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration and neurodegenerative disease. The antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or neuroactive agents and/or with other antibodies or fragments thereof. Antibodies are exemplified by the antibodies IgM12 and IgM42 whose sequences are provided herein.

    摘要翻译： 提供了能够结合并识别CNS中的神经元并引起CNS神经元中的反应的特异性结合成员，特别是人抗体，特别是重组抗体及其片段。 该抗体可用于神经保护和用于诊断和治疗与神经损伤，损伤或变性和神经变性疾病相关的病症。 本发明的抗体，可变区或CDR结构域序列及其片段也可用于与化学治疗剂，免疫调节剂或神经活性剂和/或与其它抗体或其片段组合的治疗中。 抗体以本文提供其序列的抗体IgM12和IgM42为例。

    ASSESSING RHEUMATOID ARTHRITIS
    3.
    发明申请
    ASSESSING RHEUMATOID ARTHRITIS 审中-公开
    评估湿疹风湿性关节炎

    公开(公告)号：US20120208719A1

    公开(公告)日：2012-08-16

    申请号：US13502317

    申请日：2010-10-13

    申请人： Sherine E. Gabriel ,  Keith L. Knutson ,  Larry R. Pease ,  John M. Davis

    发明人： Sherine E. Gabriel ,  Keith L. Knutson ,  Larry R. Pease ,  John M. Davis

    IPC分类号： C40B30/04

    CPC分类号： G01N33/6863 ,  G01N33/564 ,  G01N2800/102 ,  G01N2800/56

    摘要： This document provides methods and materials related to assessing mammals (e.g., humans) with arthritis (e.g., RA). For example, methods and materials for using cytokine response profiles to assist clinicians in assessing RA disease activity, assessing the likelihood of response and outcomes of RA therapy, predicting long-term RA disease outcomes, and assessing the risk of developing heart conditions are provided. Methods and materials for using cytokine response profiles to assist clinicians in diagnosing arthritis (e.g., RA) also are provided.

    摘要翻译： 本文件提供了与评估具有关节炎（例如RA）的哺乳动物（例如，人）相关的方法和材料。 例如，提供了使用细胞因子应答谱辅助临床医师评估RA疾病活动，评估RA治疗的反应和结果的可能性，预测长期RA疾病结果以及评估发展心脏病的风险的方法和材料。 还提供了使用细胞因子应答谱辅助临床医师诊断关节炎（如RA）的方法和材料。

    IgM-mediated receptor clustering and cell modulation
    5.
    发明授权
    IgM-mediated receptor clustering and cell modulation 有权

    公开(公告)号：US10202430B2

    公开(公告)日：2019-02-12

    申请号：US12738774

    申请日：2008-10-17

    申请人： Larry R. Pease ,  Moses Rodriguez

    发明人： Larry R. Pease ,  Moses Rodriguez

    IPC分类号： A61K39/00 ,  C07K14/47

    摘要： Materials and methods for using multivalent molecules (e.g., antibodies) to modulate cellular function. A molecule can be targeted to a particular type of cell, either through direct binding to an epitope on the surface of the cell, or through a linker that recognizes both the multivalent molecule and a marker on the cell surface. The invention provides a chimeric polypeptide comprising a first amino acid sequence and a second amino acid sequence, wherein the first amino acid sequence comprises an WIC Class I peptide sequence, and where the second amino acid sequence comprises an epitope to which a multivalent molecule binds, including wherein the multivalent molecule is an IgM antibody, including antibody hIgM22. The invention provides a linker molecule for targeting IgM antibody, including antibody hIgM22, to a cell in the oligodendrocyte lineage.

    Methods of promoting remyelination of central nervous system axons by administrating sHIgM22
    6.
    发明授权
    Methods of promoting remyelination of central nervous system axons by administrating sHIgM22 有权
    通过施用sHIgM22促进中枢神经系轴突再髓鞘化的方法

    公开(公告)号：US07807166B2

    公开(公告)日：2010-10-05

    申请号：US12313515

    申请日：2008-11-20

    申请人： Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

    发明人： Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

    IPC分类号： A61K39/395

    CPC分类号： A61K38/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/77 ,  C12Q1/6876 ,  Y02A50/473

    摘要： Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca−− signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22 (LYM 22), sHIgm46 (LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in diagnostic and therapeutic applications, including screening assays for the discovery of additional antibodies that bind to cells of the nervous system, particularly oligodendrocytes.

    摘要翻译： 公开了抗体，特别是人抗体，其表现出治疗脱髓鞘疾病以及中枢神经系统的病毒，细菌或特发性起源的其它疾病，包括由脊髓损伤引起的神经功能障碍的活性。 阐述神经调节剂，其包括并且包含选自能够结合中枢神经系统结构或细胞的抗体，肽类似物，半抗原，其活性片段，其激动剂，其模拟物，其单体 及其组合。 神经调节剂具有以下一个或多个特征：它能够诱导髓鞘再生; 结合神经组织; 促进少突胶质细胞的Ca-信号传导; 并促进神经胶质细胞的细胞增殖。 公开了示例性抗体的氨基酸和DNA序列。 描述了使用多克隆IgM抗体和人单克隆抗体sHIgm22（LYM22），sHIgm46（LYM46）ebvHIgM MSI19D10，CB2bG8，AKJR4，CB2iE12，CB2iE7等治疗脱髓鞘疾病和人和家畜的中枢神经系统疾病的方法， MSI19E5和MSI10E10，其活性片段等。 本发明还延伸到使用人类抗体，片段，肽衍生物和类似材料，以及它们在诊断和治疗应用中的用途，包括用于发现结合神经系统细胞，特别是少突胶质细胞的其它抗体的筛选测定。

    Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
    9.
    发明授权
    Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system 有权

    公开(公告)号：US09701745B2

    公开(公告)日：2017-07-11

    申请号：US14990325

    申请日：2016-01-07

    申请人： Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

    发明人： Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

    IPC分类号： C07K16/18 ,  C12Q1/68 ,  A61K38/00 ,  A61K39/00

    CPC分类号： A61K38/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/77 ,  C12Q1/6876 ,  Y02A50/473

    摘要： Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca−− signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in diagnostic and therapeutic applications, including screening assays for the discovery of additional antibodies that bind to cells of the nervous system, particularly oligodendrocytes.

    HUMAN IgM ANTIBODIES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF PARTICULARLY IN THE CENTRAL NERVOUS SYSTEM
    10.
    发明申请
    HUMAN IgM ANTIBODIES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF PARTICULARLY IN THE CENTRAL NERVOUS SYSTEM 有权
    人IgM抗体，其特异性的诊断和治疗用途，特别是中枢神经系统

    公开(公告)号：US20160333078A1

    公开(公告)日：2016-11-17

    申请号：US14990325

    申请日：2016-01-07

    申请人： Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

    发明人： Moses Rodriguez ,  David J. Miller ,  Larry R. Pease

    IPC分类号： C07K16/18 ,  C12Q1/68

    CPC分类号： A61K38/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/77 ,  C12Q1/6876 ,  Y02A50/473

    摘要： Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca−− signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in diagnostic and therapeutic applications, including screening assays for the discovery of additional antibodies that bind to cells of the nervous system, particularly oligodendrocytes.

    摘要翻译： 公开了抗体，特别是人抗体，其表现出治疗脱髓鞘疾病以及中枢神经系统的病毒，细菌或特发性起源的其它疾病，包括由脊髓损伤引起的神经功能障碍的活性。 阐述神经调节剂，其包括并且包含选自能够结合中枢神经系统结构或细胞的抗体，肽类似物，半抗原，其活性片段，其激动剂，其模拟物，其单体 及其组合。 神经调节剂具有以下一个或多个特征：它能够诱导髓鞘再生; 结合神经组织; 促进少突胶质细胞的Ca-信号传导; 并促进神经胶质细胞的细胞增殖。 公开了示例性抗体的氨基酸和DNA序列。 描述了使用多克隆IgM抗体和人单克隆抗体sHIgm22（LYM22），sHIgm46（LYM46）ebvHIgM MSI19D10，CB2bG8，AKJR4，CB2iE12，CB2iE7等治疗脱髓鞘疾病和人和家畜的中枢神经系统疾病的方法， MSI19E5和MSI10E10，其活性片段等。 本发明还延伸到使用人类抗体，片段，肽衍生物和类似材料，以及它们在诊断和治疗应用中的用途，包括用于发现结合神经系统细胞，特别是少突胶质细胞的其它抗体的筛选测定。